HIGHLIGHTS
- who: Carlos Rodríguez Escalera from the Torremolinos, Málaga, Spain have published the paper: Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients, in the Journal: (JOURNAL)
- what: The main reason for initiation was previous treatments lack of efficacy (69.7%) and the most common laboratory abnormalities were hypocomplementemia (40.9%) ANA + (34.2%) and anti-DNA (33.3%). According to EULAR recommendations about considering add-on treatment with belimumab in patients with inadequate response to standard-of-care , the main reason for belimumab initiation is ineffective . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.